07.22.26 -- Bridging The CGT Patient Gap, Endpoint Gaps, And Trial Friction

Delayed operational decisions around travel, payments, site workflows, meetings, and compliance can create avoidable friction for sites, participants, sponsors, and CROs once a study is underway.

Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.

Discover how specialized endpoint execution closes critical gaps in ophthalmic trials, improving assessment consistency, protocol adherence, data quality, and participant retention.

Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

With a single, consistent team from FIH to Proof-of-Concept, this Continuity Model eliminates fragmented handoffs to keep program knowledge intact and speed your path to Phase II.

Explore a platform that benefits the entire global clinical trial ecosystem by reducing complexity and operational costs while maintaining the highest standards of data security and subject privacy.

Most clinical trials face failure due to cost, design, and patient retention issues. Adopting a patient-first enterprise platform mitigates these risks in a growing, decentralized market.

We believe that delivering meaningful results begins with meeting patients where they are — whether in their homes, within their communities, or in familiar gathering places.